Literature DB >> 9789892

Methotrexate for sarcoidosis.

R P Baughman1.   

Abstract

Treatment options for sarcoidosis include corticosteroids, anti-inflammatory agents and cytotoxic drugs. Methotrexate is a cytotoxic agent which has been used with increasing frequency in the patient with chronic disease. The drug has been useful for various manifestations of the disease, including chronic lung and skin disease. The toxicity of the methotrexate is usually limited to hematologic and hepatic toxicity. Long term use of the drug is associated with some toxicity. Liver biopsies have proved a useful way of identifying which patients may remain on therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9789892

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  6 in total

1.  Secondary and Infiltrative Cardiomyopathies.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-10

2.  Sarcoidosis with hepatic involvement in a 60-year-old patient.

Authors:  Luutsen van Houten; Maarten Horst; Suzy Samii
Journal:  J Radiol Case Rep       Date:  2022-03-01

Review 3.  Obstructive sarcoidosis.

Authors:  Petey Laohaburanakit; Andrew Chan
Journal:  Clin Rev Allergy Immunol       Date:  2003-10       Impact factor: 8.667

4.  Methotrexate treatment efficacy in sarcoidosis might be related to TNF-α polymorphism: real life preliminary study.

Authors:  Anna Goljan Geremek; Elzbieta Puscinska; Monika Czystowska; Agnieszka Skoczylas; Michal Bednarek; Adam Nowinski; Dorota Gorecka; Urszula Demkow; Pawel Sliwinski
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

Review 5.  Hepatic Sarcoidosis.

Authors:  Micheal Tadros; Faripour Forouhar; George Y Wu
Journal:  J Clin Transl Hepatol       Date:  2013-12-15

6.  A comparison of vitamin A and leucovorin for the prevention of methotrexate-induced micronuclei production in rat bone marrow.

Authors:  Sampath Madhyastha; Latha V Prabhu; V Saralaya; Rajalakshmi Rai
Journal:  Clinics (Sao Paulo)       Date:  2008-12       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.